Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6

Vicki L Ellingrod; Susan K Schultz; Stephan Arndt

doi:10.1592/phco.22.16.1416.33700

Back

Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6

Journal article

Peer reviewed

Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6

Vicki L Ellingrod, Susan K Schultz and Stephan Arndt

Pharmacotherapy, Vol.22(11), pp.1416-1419

11/2002

DOI: 10.1592/phco.22.16.1416.33700

PMID: 12432967

View Online

Abstract

To investigate the relationships between cytochrome P450 (CYP) 2D6 genotype, antipsychotic drug exposure, abnormal movements and tardive dyskinesia, and cigarette smoking. Prospective, longitudinal study. University mental health research center. Thirty-seven patients with schizophrenia. Patients were genotyped for CYP2D6*1, *3, and *4 alleles, and data were collected on their psychiatric symptoms, cigarette smoking status, and antipsychotic drug exposure. Abnormal movements were measured using the Abnormal Involuntary Movement Scale (AIMS). Presence of tardive dyskinesia was also evaluated. A linear regression model used the AIMS scores as the dependent variable, and genotype, sex, smoking status, and antipsychotic drug exposure as independent variables. Antipsychotic drug exposure, genotype, and cigarette smoking interaction was significant (p<0.0212) for patients with the CYP2D6*1/*3, *4 genotype. Seventy-eight percent of smokers with the CYP2D6*1/*3, *4 genotype had tardive dyskinesia compared with 20-33% of patients in other groups. Patients with a CYP2D6*3 or *4 allele may shunt antipsychotic metabolism through other pathways that are induced by cigarette smoke. This induction may result in formation of neurotoxic metabolites, leading to increased AIMS scores and a higher frequency of tardive dyskinesia compared with patients without these alleles.

Adult

Antipsychotic Agents - adverse effects

Antipsychotic Agents - therapeutic use

Cytochrome P-450 CYP2D6 - genetics

Dyskinesia, Drug-Induced - enzymology

Dyskinesia, Drug-Induced - genetics

Dyskinesias - enzymology

Dyskinesias - genetics

Female

Genotype

Humans

Linear Models

Male

Middle Aged

Prospective Studies

Schizophrenia - drug therapy

Schizophrenia - enzymology

Schizophrenia - genetics

Smoking - genetics

Smoking - metabolism

Details

Title: Subtitle: Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6
Creators: Vicki L Ellingrod - University of Iowa
Susan K Schultz - University of Iowa
Stephan Arndt - University of Iowa
Resource Type: Journal article
Publication Details: Pharmacotherapy, Vol.22(11), pp.1416-1419
DOI: 10.1592/phco.22.16.1416.33700
PMID: 12432967
ISSN: 0277-0008
eISSN: 1875-9114
Language: English
Date published: 11/2002
Academic Unit: Psychiatry; Biostatistics; Nursing; Injury Prevention Research Center
Record Identifier: 9985132187602771

Metrics

1 Record Views

See more details